Peter Dull

7.3k citations

88 papers · 4.4k indexed · 1 hit paper · h-index 38

Impact in

Microbiology top 0.05%
- Bacterial Infections and Vaccines
Epidemiology top 0.5%
- Pneumonia and Respiratory Infections
- Influenza Virus Research Studies
- Virology and Viral Diseases
- Respiratory viral infections research

Papers in ⓘ

Microbiology 65
- Bacterial Infections and Vaccines 65
Epidemiology 71
- Pneumonia and Respiratory Infections 62
- Influenza Virus Research Studies 31
- Virology and Viral Diseases 12
- Respiratory viral infections research 9
- Hepatitis B Virus Studies 4

Co-authors: Daniela Toneatto (20 shared papers)Lisa Bedell (11 shared papers)Andrew Fioré-Gartland (2 shared papers)Stanley A. Plotkin (3 shared papers)George R. Siber (2 shared papers)Donna M. Ambrosino (2 shared papers)David Goldblatt (2 shared papers)Roman Prymula (8 shared papers)
Journals: Vaccine (21 papers)The Pediatric Infectious Disease Journal (11 papers)Human Vaccines & Immunotherapeutics (5 papers)International Journal of Infectious Diseases (4 papers)JAMA (4 papers)
Partner nations: United States United Kingdom Italy

In The Last Decade

Peter Dull

86 papers receiving 4.2k citations

Hit Papers

align trajectories log scale

Evidence for antibody as a protective correlate for COVID-19 vaccines 2021 · 475 citations

Peers

Countries citing papers authored by Peter Dull

Since Specialization

Citations

This map shows the geographic impact of Peter Dull's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Dull with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Dull more than expected).

Fields of papers citing papers by Peter Dull

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Dull. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Dull. The network helps show where Peter Dull may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Dull, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Dull Line = papers co-authored together Peter Dull links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 88 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Evidence for antibody as a protective correlate for COVID-19 vaccines Vaccine ·Kristen Earle, Donna M. Ambrosino, Andrew Fioré-Gartland, David Goldblatt, Peter B. Gilbert, George R. Siber, Peter Dull, Stanley A. Plotkin Hit paper breakdown →	2021	475
2	Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules JAMA ·Nicoletta Gossger, Matthew D. Snape, Ly‐Mee Yu, Adam Finn, Gianni Bona, Susanna Esposito, Nicola Principi, Javier Díez‐Domingo, Étienne Sokal, Birgitta Becker, Dorothee Kieninger, Roman Prymula, Peter Dull, Ellen Ypma, Daniela Toneatto, Alan Kimura, Andrew J. Pollard, for the European MenB Vaccine Study Group	2012	217
3	Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials The Lancet ·Timo Vesikari, Susanna Esposito, Roman Prymula, Ellen Ypma, Igor Kohl, Daniela Toneatto, Peter Dull, Alan Kimura	2013	209
4	Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study The Lancet ·Marı́a Elena Santolaya, Miguel L. O’Ryan, María Teresa Valenzuela, Valeria Prado, Rodrigo Vergara, Alma Muñoz, Daniela Toneatto, Gabriela Graña, Huajun Wang, Ralf Clemens, Peter Dull	2012	199
5	Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants JAMA ·Matthew D. Snape, Kirsten P. Perrett, Karen Ford, Tessa M. John, David Pace, Ly‐Mee Yu, Joanne M. Langley, Shelly McNeil, Peter Dull, Francesca Ceddia, Alessandra Anemona, Scott A. Halperin, Simon Dobson, Andrew J. Pollard	2008	162
6	THE ETIOLOGY OF FEBRILE ILLNESS IN ADULTS PRESENTING TO PATAN HOSPITAL IN KATHMANDU, NEPAL American Journal of Tropical Medicine and Hygiene ·David Murdoch, Christopher W. Woods, Mark Zimmerman, Peter Dull, Ram Belbase, ANDREW J. KEENAN, Robert McNair Scott, Buddha Basnyat, Lennox K. Archibald, L. Barth Reller	2004	159
7	A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program Drugs ·Miguel O’Ryan, Jeffrey J. Stoddard, Daniela Toneatto, James Wassil, Peter Dull	2013	128
8	Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial The Lancet Infectious Diseases ·Shabir A. Madhi, Clare Cutland, Lisa Jose, Anthonet Koen, Niresha Govender, Frederick Wittke, Morounfolu Olugbosi, Ajoke Sobanjo-ter Meulen, Sherryl Baker, Peter Dull, Vas Narasimhan, Karen S. Slobod	2016	119
9	Immune Responses toBacillus anthracisProtective Antigen in Patients with Bioterrorism‐Related Cutaneous or Inhalation Anthrax The Journal of Infectious Diseases ·Conrad P. Quinn, Peter Dull, Vera Semenova, Han Li, Shane Crotty, Thomas H. Taylor, Evelene Steward‐Clark, Karen Stamey, Daniel S. Schmidt, Kelly Wallace Stinson, Alison Freeman, Cheryl M. Elie, Sandra K. Martin, Carolyn M. Greene, Rachael D. Aubert, John Glidewell, Bradley A. Perkins, Rafi Ahmed, David S. Stephens	2004	101
10	Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants Vaccine ·Shabir A. Madhi, Ziyaad Dangor, Paul T. Heath, Stephanie J. Schrag, Alaine Izu, Ajoke Sobanjo-ter Meulen, Peter Dull	2013	95
11	Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine ·Eva Hong, Marzia Monica Giuliani, Ala‐Eddine Deghmane, Maurizio Comanducci, Brunella Brunelli, Peter Dull, Mariagrazia Pizza, Muhamed‐Kheir Taha	2012	89
12	Towards a population-based threshold of protection for COVID-19 vaccines Vaccine ·David Goldblatt, Andrew Fioré-Gartland, Marina Johnson, Adam Hunt, Christopher Bengt, Dace Zavadska, Hilda Darta Snipe, Jeremy Brown, Lesley Workman, Heather J. Zar, David C. Montefiori, Xiaoying Shen, Peter Dull, Stanley A. Plotkin, George R. Siber, Donna M. Ambrosino	2021	87
13	Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents Clinical Infectious Diseases ·Lisa A. Jackson, Roger Baxter, Keith S. Reisinger, Annette Karsten, Jina Shah, Lisa Bedell, Peter Dull, (unknown)	2009	87
14	Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial The Lancet Infectious Diseases ·Robert S. Heyderman, Shabir A. Madhi, Neil French, Clare Cutland, Bagrey Ngwira, Doris Kayambo, Robert Mboizi, Anthonet Koen, Lisa Jose, Morounfolu Olugbosi, Frederick Wittke, Karen S. Slobod, Peter Dull	2016	84
15	A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I) Human Vaccines & Immunotherapeutics ·Roman Prymula, Susanna Esposito, Gianvincenzo Zuccotti, Fang Xie, Daniela Toneatto, Igor Kohl, Peter Dull	2014	81
16	Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM ₁₉₇ Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates Clinical and Vaccine Immunology ·Alan Kimura, Daniela Toneatto, A. Kleinschmidt, Wang Hua-jun, Peter Dull	2010	78
17	Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents Human Vaccines ·Christopher Gill, Roger Baxter, Alessandra Anemona, Giuseppe Ciavarro, Peter Dull	2010	75
18	The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans Human Vaccines ·Daniela Toneatto, Shevqet Ismaili, Ellen Ypma, Kay Vienken, Philipp Oster, Peter Dull	2011	71
19	Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages Vaccine ·Michael Bröker, Peter Dull, Rino Rappuoli, Paolo Costantino	2009	70
20	Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine Obstetrics and Gynecology ·Gilbert Donders, Scott A. Halperin, Roland Devlieger, Sherryl Baker, Pietro Forte, Frederick Wittke, Karen S. Slobod, Peter Dull	2016	70

About Peter Dull

Peter Dull is a scholar working on Microbiology, Epidemiology, Public Health, Environmental and Occupational Health, Infectious Diseases and Health, having authored 88 papers that have together received 4.4k indexed citations. Recurring topics across this work include Bacterial Infections and Vaccines (65 papers), Pneumonia and Respiratory Infections (62 papers), Influenza Virus Research Studies (31 papers), Virology and Viral Diseases (12 papers), Neonatal and Maternal Infections (9 papers), Respiratory viral infections research (9 papers), Streptococcal Infections and Treatments (8 papers) and Hepatitis B Virus Studies (4 papers). The work is most often cited by research in Microbiology (2.6k citations), Epidemiology (3.0k citations), Infectious Diseases (934 citations), Health (360 citations) and Endocrinology (126 citations). Peter Dull has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Daniela Toneatto, Lisa Bedell, Andrew Fioré-Gartland, Stanley A. Plotkin, George R. Siber, Donna M. Ambrosino, David Goldblatt, Roman Prymula, Peter B. Gilbert and Kristen Earle. Their work appears in journals such as Vaccine, The Pediatric Infectious Disease Journal, Human Vaccines & Immunotherapeutics, International Journal of Infectious Diseases and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact